The Conversation (0)
Cancer Genetics released their financial report for the third quarter of 2017.
Cancer Genetics (NASDAQ:CGIX) released their financial report for the third quarter of 2017.
As quoted in the press release:
Mr. Panna Sharma, President and CEO of CGI commented, “During the third quarter of 2017 we continued to advance our business growth through execution of targeted strategic initiatives. We are pleased to have delivered a record quarter of revenue along with a significant bottom line improvement, and are committed to achieving profitability in the near-term.
“Cancer Genetics continues to be a leader in working with biopharma companies to realize the potential of precision oncology and to bring new, life-saving therapies to patients across a wide range of oncology indications. Our 134% increase in contracted revenue is illustrative of the high value the biopharma industry puts on the expertise that CGI brings to drug development, as well as the strategic focus of the Company to be the premier partner for drug discovery and development in oncology. We are extremely proud to be actively working with nine of the top ten biopharma companies, which is a testament to our unique business model and capabilities.”
Click here to read the full press release.
Source: globenewswire.com